Tadalafil Tablets vs Oral Suspension: Product and Formulation Context

Tadalafil Tablets vs Oral Suspension at a Glance

The clearest difference is how the finished product expresses and delivers tadalafil. A tablet contains a fixed number of milligrams in one solid unit, while a suspension contains tadalafil at a defined concentration and requires a measured volume to deliver a particular milligram amount.

The regulatory context is equally important. Tadalafil tablets are not one single product category with one indication, and TADLIQ should not be treated as a liquid version of every tablet carrying the tadalafil name.

Tadalafil Tablets Are a Dosage-Form Category, Not One Regulatory Product

The phrase tadalafil tablets can describe multiple finished products. Generic tadalafil tablet labels used in the ED/BPH context document 2.5 mg, 5 mg, 10 mg and 20 mg strengths, while ADCIRCA is a distinct tadalafil tablet product supplied at 20 mg for pulmonary arterial hypertension.

That means a comparison between 'tablets' and 'liquid' first needs to identify which tablet product is the relevant comparator. A Cialis-related ED/BPH tablet and an Adcirca-related PAH tablet share tadalafil but do not have the same product identity or labeled therapeutic framework.

The broader tablet category is covered on the tadalafil tablets page.

TADLIQ Is a Specific Tadalafil Oral-Suspension Product

TADLIQ is not simply a descriptive name for compounded or generic liquid tadalafil. It is a specific U.S. prescription product supplied as tadalafil oral suspension at 20 mg per 5 mL.

The suspension is described as white to off-white, opaque and peppermint flavored and is supplied in a 150 mL bottle. Its current labeling identifies pulmonary arterial hypertension WHO Group 1 as the indication and uses a 40 mg, or 10 mL, once-daily regimen in that labeled context.

Brand-specific details are covered on the TADLIQ page, while the dosage-form category is covered on tadalafil oral suspension.

Dosage Form Does Not Determine Tadalafil's Labeled Use

It would be inaccurate to say that tadalafil tablets are for erectile dysfunction while liquid tadalafil is simply another way to treat the same indication. Tablet tadalafil exists under several different labels, and some tablet products are specifically used in the PAH context.

CIALIS and many corresponding tadalafil tablet labels include ED and BPH contexts. ADCIRCA, by contrast, is a 20 mg tablet product labeled for PAH, while TADLIQ is an oral suspension labeled for PAH.

Disease-specific tadalafil use is discussed separately on tadalafil for pulmonary hypertension.

TADLIQ's Most Relevant Tablet Comparator Is ADCIRCA

TADLIQ's U.S. development program was tied specifically to the PAH tablet product ADCIRCA rather than to tadalafil tablets as an undifferentiated category. FDA's clinical pharmacology review states that the 505(b)(2) application relied on the Agency's findings for ADCIRCA tablets.

The review compared 5 mL of the 4 mg/mL tadalafil suspension, corresponding to 20 mg tadalafil, with one 20 mg ADCIRCA tablet under fasting conditions. This creates a direct product-specific scientific bridge between those formulations.

ADCIRCA itself is covered on the ADCIRCA page; the existence of this comparison should not be generalized to every tadalafil tablet sold in every market.

FDA Review Found TADLIQ Bioequivalent to ADCIRCA in the Studied Fasting Comparison

FDA's clinical pharmacology review concluded that TADLIQ was bioequivalent to the 20 mg ADCIRCA tablet under the studied fasting conditions. The test-to-reference ratio for Cmax was 95.5% with a 90% confidence interval of 89.9% to 101.4%, while the AUC0-72h ratio was 99.5% with a 90% confidence interval of 94.4% to 104.9%.

Those results are strong evidence for the specific formulation comparison supporting the TADLIQ application. They do not mean that every tadalafil oral suspension is bioequivalent to every tablet product or that another liquid can inherit TADLIQ's regulatory evidence.

The regulatory meaning of these PK comparisons is explained more broadly on the tadalafil bioequivalence page.

Bioequivalence Evidence Does Not Mean Every Tablet and Suspension Are Automatically Interchangeable

TADLIQ's bioequivalence evidence is important, but its scope needs to remain precise. The study compared one defined oral suspension with one defined reference tablet at a specified dose and under specified study conditions.

It does not create a general rule allowing any tadalafil tablet to be replaced milligram-for-milligram with any liquid formulation. Different products can have different indications, concentrations, inactive ingredients, labeling, regulatory applications and preparation instructions.

Interchangeability or substitution questions therefore need to be answered from the exact product labeling and applicable regulatory framework rather than from the active ingredient alone.

Tablets Use Strength per Unit; Suspension Uses Concentration and Volume

Tablet labeling typically expresses tadalafil as a fixed strength for each tablet, such as 5 mg, 10 mg or 20 mg. A liquid product needs an additional dimension because its drug content is distributed through a volume.

TADLIQ contains 20 mg tadalafil in 5 mL, which corresponds to 4 mg/mL. Under its PAH label, 40 mg is therefore represented as 10 mL of the suspension.

This arithmetic describes the TADLIQ formulation and label; it should not be turned into a homemade conversion rule for unrelated liquid tadalafil products.

The PAH Labels Show the Same Tadalafil Amount Delivered Differently

In the current ADCIRCA label, the standard PAH regimen is 40 mg once daily, supplied as two 20 mg tablets. In the TADLIQ label, the corresponding 40 mg amount is expressed as 10 mL of the 20 mg/5 mL suspension.

This provides a straightforward example of dosage-form difference: fixed solid units on one side and a measured liquid volume on the other. The pharmacologic milligram amount can align while the finished-product handling remains different.

These are label-specific PAH examples rather than general instructions for converting unrelated tadalafil products.

Oral Suspension Requires Product Preparation and Volume Measurement

A suspension contains particles dispersed through a liquid vehicle rather than a premeasured solid tablet unit. For TADLIQ, the label specifically instructs that the bottle be shaken well for 30 seconds before the dose is measured.

That preparation step is a meaningful practical difference from a fixed-strength tablet. Tablet administration does not require redistribution of suspended drug through a bottle before the individual unit is taken.

These handling differences belong to the finished formulation and should not be interpreted as differences in tadalafil's basic molecular mechanism.

Packaging Reflects the Different Finished-Product Designs

Tablets are supplied as discrete dosage units in product-specific bottles or blister presentations. TADLIQ is supplied as a multidose 150 mL bottle containing peppermint-flavored oral suspension.

The TADLIQ label also provides suspension-specific storage and handling instructions, including controlled room-temperature storage and shaking before use. Those requirements are part of the approved finished product rather than general properties of tadalafil.

Packaging therefore contributes to product identity even when the active ingredient is the same.

Tablet and Suspension Formulations Use Different Inactive-Ingredient Systems

A liquid suspension requires formulation components that maintain physical stability, palatability and preservation in a multidose bottle. TADLIQ includes ingredients such as xanthan gum, glycerin, sodium benzoate, sucralose and peppermint flavor in addition to tadalafil.

Tablet products use their own product-specific inactive ingredients and manufacturing systems. Sharing tadalafil as the active molecule therefore does not mean the complete formulations are compositionally identical.

These differences are normal finished-product characteristics and should be distinguished from the question of whether a specific test and reference formulation has appropriate bioequivalence evidence.

Food Instructions Are Product-Label Questions, Not Assumptions Based on Dosage Form

Both the current TADLIQ and ADCIRCA labels permit administration with or without food in their PAH contexts. The TADLIQ development program also specifically evaluated food effect as part of its clinical pharmacology assessment.

FDA's review reported modest increases in tadalafil exposure for the suspension after a high-fat meal compared with fasting, but considered those increases not clinically significant for the approved product. The resulting TADLIQ label permits dosing with or without food.

This conclusion belongs to the studied TADLIQ product and should not be generalized to every unverified tadalafil liquid formulation.

Changing Dosage Form Does Not Change Tadalafil's Core Mechanism

Both properly identified tadalafil tablets and TADLIQ deliver tadalafil, a phosphodiesterase type 5 inhibitor. The core molecular action therefore comes from the active drug rather than from whether it is formulated as a tablet or suspension.

Formulation can affect how a product is supplied, measured, administered and evaluated for bioavailability, but it does not create a new pharmacologic target. The mechanism itself is covered on how tadalafil works.

This distinction helps prevent practical dosage-form differences from being confused with a different active medicine.

Core Tadalafil Safety Principles Carry Across Forms, but Labels Still Matter

Because both dosage forms contain tadalafil, major active-ingredient safety principles remain relevant. Current TADLIQ and ADCIRCA labels both include contraindications involving organic nitrates and guanylate cyclase stimulators.

That shared safety framework does not make all tadalafil labels interchangeable. Indication-specific warnings, dose adjustments, product preparation and administration instructions still need to come from the exact finished product being used.

Detailed active-ingredient safety belongs on tadalafil contraindications, tadalafil drug interactions and tadalafil side effects.

TADLIQ Should Not Simply Be Described as 'Liquid Cialis'

Calling TADLIQ liquid Cialis would obscure important product differences. Both contain tadalafil, but current CIALIS labeling centers on ED and BPH contexts, while TADLIQ is specifically labeled for PAH WHO Group 1.

TADLIQ's regulatory development relied on ADCIRCA as its reference listed drug rather than using Cialis as the direct formulation comparator. This makes ADCIRCA the more relevant tablet relationship when explaining why the TADLIQ PAH label exists.

CIALIS as a branded product is covered separately on the Cialis page.

Milligram Equivalence Is Not the Same as a General Substitution Rule

Mathematically, TADLIQ's 4 mg/mL concentration allows the tadalafil amount in a measured volume to be calculated directly. For example, 5 mL contains 20 mg and 10 mL contains 40 mg.

That arithmetic does not authorize converting a person's existing tablet regimen to suspension without reference to the specific product label and clinical context. Tablet products can have different indications and dosing frameworks even when the same number of milligrams appears on the label.

General dose frameworks are covered on the tadalafil dosage page rather than being derived from dosage-form arithmetic.

Choosing a Dosage Form Is a Product and Clinical Question

A dosage-form comparison can identify practical differences such as fixed tablet units versus measured liquid volume, but it should not declare one form universally better. The appropriate product depends on the approved indication, available formulation, labeling and individual clinical circumstances.

TADLIQ provides an FDA-approved oral-suspension option in its PAH context. That fact is different from claiming that suspension should replace tablets generally or that it has broader indications than the label establishes.

Product identity should therefore come before convenience comparisons.

How to Verify a Tablet-vs-Suspension Tadalafil Claim

The product name and label should be checked before comparing dosage forms. DailyMed and FDA records can establish whether a tadalafil product is a tablet or suspension, its strength or concentration, labeled indication and product-specific administration instructions.

For TADLIQ, the FDA clinical pharmacology review provides additional evidence linking the oral suspension to ADCIRCA through a defined bioequivalence study. That level of evidence should not be replaced by a general statement that two products contain tadalafil.

A pharmacy listing or informal reference to liquid tadalafil is not enough to establish TADLIQ's concentration, approved indication or bioequivalence relationship.

Common Misunderstandings About Tadalafil Tablets and Oral Suspension

A common mistake is to assume that oral suspension is simply liquid tadalafil tablets with no product-level differences. TADLIQ has its own concentration, bottle presentation, administration instructions, approved application and labeled PAH use.

Another mistake is to assume that equal milligrams guarantee general interchangeability. TADLIQ has specific bioequivalence evidence relative to ADCIRCA, but that finding cannot be extended automatically to every tadalafil tablet or every liquid formulation.

Finally, TADLIQ should not be called liquid Cialis simply because both products contain tadalafil; their labeled indication contexts are different.

Key Takeaways: Tadalafil Tablets vs Oral Suspension

Tadalafil tablets deliver fixed milligram amounts in solid dosage units, whereas TADLIQ delivers tadalafil as a 20 mg/5 mL oral suspension that requires volume measurement and shaking before use. These formulation differences affect product handling but do not change tadalafil's core PDE5 pharmacology.

Indication and regulatory identity are more important than dosage form alone. Tablet tadalafil includes both ED/BPH and PAH product contexts, while TADLIQ is specifically labeled for PAH and was developed in relation to the 20 mg ADCIRCA tablet product.

FDA review found TADLIQ bioequivalent to ADCIRCA in the specific fasting formulation study supporting its application. That evidence is product-specific and should not be converted into a blanket claim that every tadalafil suspension is interchangeable with every tadalafil tablet.